239 related articles for article (PubMed ID: 26119960)
1. Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies.
Lu S; Yu Y; Chen Z; Ye X; Li Z; Niu X
Lung; 2015 Oct; 193(5):805-14. PubMed ID: 26119960
[TBL] [Abstract][Full Text] [Related]
2. Maintenance or Consolidation Therapy for Non--Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects.
Zhang C; Huang C; Wang J; Wang X; Li K
Clin Lung Cancer; 2015 Sep; 16(5):e15-23. PubMed ID: 25676720
[TBL] [Abstract][Full Text] [Related]
3. The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.
Zhang L; Gao S; He J
Drug Des Devel Ther; 2017; 11():3435-3440. PubMed ID: 29238168
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
[TBL] [Abstract][Full Text] [Related]
6. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
Li BT; Barnes TA; Chan DL; Naidoo J; Lee A; Khasraw M; Marx GM; Kris MG; Clarke SJ; Drilon A; Rudin CM; Pavlakis N
Lung Cancer; 2016 Dec; 102():21-27. PubMed ID: 27987583
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
Qi WX; Shen Z; Yao Y
Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
Zhong A; Xiong X; Shi M; Xu H
Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Jiang J; Huang L; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
Acta Oncol; 2011 May; 50(4):582-8. PubMed ID: 21190510
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Zhang X; Zang J; Xu J; Bai C; Qin Y; Liu K; Wu C; Wu M; He Q; Zhang S; Wei L; He J
Chest; 2011 Jul; 140(1):117-126. PubMed ID: 21436247
[TBL] [Abstract][Full Text] [Related]
11. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
[TBL] [Abstract][Full Text] [Related]
12. Maintenance treatment with different strategies in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Cai H; Lin Y; Li W; Li X
Clin Lung Cancer; 2013 Jul; 14(4):333-41. PubMed ID: 23276822
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.
Chiappori AA; Kolevska T; Spigel DR; Hager S; Rarick M; Gadgeel S; Blais N; Von Pawel J; Hart L; Reck M; Bassett E; Burington B; Schiller JH
Ann Oncol; 2015 Feb; 26(2):354-62. PubMed ID: 25467017
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Sheng Z; Zhang Y
Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
[TBL] [Abstract][Full Text] [Related]
16. Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.
Suzuki H; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Kawase I
Asia Pac J Clin Oncol; 2015 Jun; 11(2):121-8. PubMed ID: 24811212
[TBL] [Abstract][Full Text] [Related]
17. The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials.
Li G; Gao S; Sheng Z; Li B
Chemotherapy; 2016; 61(4):179-89. PubMed ID: 26859739
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
[TBL] [Abstract][Full Text] [Related]
19. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE
J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.
Yu S; Xu Q; Yuan Y; Li X; Cai H
Curr Med Res Opin; 2016 Dec; 32(12):1927-1934. PubMed ID: 27479336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
